It amazes me that they were facing a respiratory virus "pandemic" and the first thing they reach for is a sedation for end of life care. Does it not make more sense to look to the arsenal you have and use in every previous respiratory infection outbreak and make sure that you have all the treatments for this in abundance, the last thing should be a respiratory depressant.
Three years later the indispensable truth of the Italian story is once you scratch beneath the surface of the official narrative of the Covid Pandemic it turns out to be a bottomless snake pit of distortions, manipulations and outright lies.
Any excess deaths in Spring 2020 in Northern Italy were an artifact of already existing health conditions in an aging population, the obliteration of the existing health care infrastructure, massive industrial pollution creating chronic conditions, media generated hysteria, savage government lockdowns and administrative murder of the already fragile.
These iatrogenic deaths of fragile people were the result of the social order and public health despotism and then used to give the impression that there was “a deadly virus” circulating.
The only pandemic was one of violent government and biomedical assault against people.
The evidence from Italy in 2020 exposes the official “Covid” narrative for what it is- a cold-blooded organized deception.
In France, a GP in the country published a letter she received with instructions what to do in case she suspected an elderly person presents with "Covid symptoms". = give them Hypnovel = Midazolam. This letter was a cilculaire sent to all GPs,
She was so socked that she published the letter and I believe retired from her post after.
2) A Midazolam injection shortage in the U.S. reported was by the FDA on Apr 2, 2020. (Midazolam = Versed, made by Pfizer) When I asked someone I know who works in the medical supply industry about the shortage, she said by the time such shortages are reported by the FDA, it's "old news" to those who are doing the purchasing (for hospitals, etc.). She was quite surprised when I showed her the timing (April 2, 2020), because the implication is that there was very high use in the preceding weeks, if not months. A group of "experts" even wrote a letter to states that use the drug in capital punishment, requesting them to release it from their stockpiles to help treat COVID patients. https://www.theguardian.com/us-news/2020/apr/13/death-penalty-states-coronavirus-stockpiled-drugs I have mixed views on what was behind this letter, but at the time, it helped push the Deadly Spreading Virus narrative...and the idea that such drugs were "needed" for placing/sustaining patients on ventilators.
3) High doses of midazolam were reported for use during with ICU patients in this study of medications used in 47 NY hospitals. https://pubmed.ncbi.nlm.nih.gov/32712675/ I continue to be disturbed by the rhythmic nature of the census (blue) line.
4) Typical doses of midazolam are "associated with respiratory depression and cardiac arrest when used in combination with an opioid, particularly in the elderly, although all ages are at risk for respiratory depression," per this 1997 review https://pubmed.ncbi.nlm.nih.gov/9258787/
5) In 2014, Emergency Medical Services in Chicago implemented a new protocol for management of patients with behavioral emergencies using midazolam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234702/ I would love to know how many & which big-city EMS systems in the U.S. and elsewhere had also normalized using the drug in this manner prior to 2020. Noteable finding: Six adverse events in which midazolam was the suspected culprit: hypotension, hypoxia, unresponsiveness, traumatic cardiac arrest (n =1), and worsening agitation (n = 2). For the nine cases, all happened after a single 5 mg dose administered via IM (n = 6) or IN (n = 3) routes. Two of those involved giving midazolam after naloxone was administered (opioid OD drug). Such effects remind me of the hypoxia reports out of NYC and unusual number of younger-adult COVID deaths in hospitals...
Our study found that COVID+ve decedents received significantly higher opioid doses than matched prepandemic or intrapandemic control patients. This finding was moderately robust: it was consistent in each 24-hour time period within the last 72 hours of life, and further
bolstered by finding that dying of COVID-19 was independently associated (aOR=2.6) with a parenteral MEDD≥30 mg in the last 24 hours of life. COVID+ve decedents had significantly higher maximum 24-hour propofol use in ICU compared with control group decedents. Also, higher lorazepam and midazolam doses were used in the COVID+ve group than either of the other groups; the difference was only statistically significant in relation to lorazepam. Collectively, these findings regarding opioid and sedative use support our study hypothesis that the requirement for these medications is higher in hospitalised patients dying of COVID-19 infection.
In subgroup analyses, COVID+ve ICU decedents had significantly higher opioid use than ICU decedents in either of the control groups, which was evident in the last 24 hours (T1) and over the last 72 hours of life, suggesting that dying in ICU with COVID-19 infection is particularly associated with increased opioid and propofol requirements. These findings warrant a symptom profile evaluation of those dying of COVID-19.
A spokesperson from Accord Healthcare, one of five manufacturers of the drug, told The Pharmaceutical Journal that it had to gain regulatory approval to sell French-labelled supplies of midazolam injection to the NHS, after having already sold two years’ worth of stock to UK wholesalers “at the request of the NHS” in March 2020.
The DHSC said the request for extra stock was part of “national efforts to respond to the coronavirus outbreak”, which included precautions “to reduce the likelihood of future shortages”.
Midazolam is listed by the Royal College of Anaesthetists as a “first-line” sedative in the management of COVID-19 patients, and warns in guidance published on 2 April 2020 that it “may be subject to demand pressure”.
Matt Hancock, the UK health secretary, told the House of Commons Health and Social Care Select Committee on 17 April 2020 that intensive therapy unit medicines — including midazolam — are part of “a delicate supply chain” as they “are made in a relatively small number of factories around the world”.
While the DHSC confirmed that midazolam is still available to both primary and secondary care, it added that some suppliers of the sedative had limited or no stock availability.
A spokesperson from Accord Healthcare told The Pharmaceutical Journal on 11 May 2020 that it was out of stock of midazolam injection after the NHS requested it “place all of its stock of midazolam — equivalent to around two year’s forecasted supply — into its wholesale partners”, even though the manufacturer “does not currently have any NHS contracts in England” to supply the drug.
“As a result of the NHS request [in March 2020], we are subsequently out of stock,” said Peter Kelly, managing director of Accord Healthcare.
However, he added that the Medicines and Healthcare products Regulatory Agency (MHRA) had given the manufacturer approval “for some French label stock — another 22,000 packs — to be sold into the NHS and [we] are currently waiting for the MHRA’s direction on where to place the stock”.
The manufacturer said the French stock only includes midazolam at the strength of 1mg/mL in 5mL, while the initial supply in March 2020 contained a variety of four different strengths.
Seizure Drug Approval Expands Countermeasures for Chemical Weapons Attack
"The U.S. Food and Drug Administration approval in Sep 2018 of the drug Seizalam® (midazolam injection) as an anti-seizure medication, provided the nation with a medical countermeasure (MCM) for people exposed to chemicals that cause prolonged seizures, whether those situations are in combat, domestic accidents or an intentional attack.
Developed by Meridian Medical Technologies, Midazolam originally was approved by FDA for use as a sedative. This recent FDA approval of intramuscular midazolam (tradename Seizalam) for status epilepticus expands the possible uses of the drug."
Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units
Tension in the supply of highly consumed drugs for patients with COVID-19 (propofol, midazolam, curares) led the French government to set up a centralized supply of hospitals with distribution based on the number of resuscitation beds in March 2020.
...
Results
For the 358 establishments (47% public, 53% private), dispensations in CCU in March 2020 compared to March 2019 increased, respectively: propofol (+81%), midazolam (+125%), cisatracurium (+311%), atracurium (+138%), rocuronium (+119%); and decreased for anaesthesia: propofol (−27%), midazolam (-10%), cisatracurium (−19%), atracurium (−27%), rocuronium (+16%).
...
Conclusions
Variation of dispensations between CCU and others was directly related to the increase of COVID patients in CCU and the decrease in surgical activity.
...
During the first wave of the COVID-19 pandemic, the maximal alert in French hospitals was announced on March 13th 2020. Consequently, non-urgent surgical activity was postponed or cancelled. Priority was given to Intensive Care Units (ICU) for fear of running out of essential drugs for critical care patients.
...
The status of stocks of targeted drugs (propofol, midazolam, atracurium, cisatracurium, rocuronium) was already registered in the "MaPUI" software (MaPUI Labs, Cesson Sévigné, France), created for this purpose by a French start-up.
...
The variation of dispensations April 2019 / April 2020 for critical care units further evolved and resulted in an increase, respectively: propofol (+165%), midazolam (+204%), cisatracurium (+302%), atracurium (+350%), rocuronium (+43%). For anesthesia, it resulted in a decrease: propofol (−70%), midazolam (−67%), cisatracurium (−55%), atracurium (−65%), rocuronium (0%).
A shortage of at least one of the five drugs concerned by the survey was reported by 28% of establishments.
The use of parenteral fentanyl showed an increase in the total consumption in 2020 compared to 2019 (216,817,273 × 171,240,825 mcg). In 2019, consumption was stationary, with the highest mean weekly consumption being 588 mcg in EW 10. On the other hand, in 2020, there were two significant upward trends in total consumption, coinciding with the two waves of Covid-19 (gamma and delta variants of SARS-CoV-2).
The absolute number of patients included in 2020 was lower than in 2019 (310,281 × 401,602) (Table 2 and Fig. 5). Despite this reduction, mean opioid consumption per patient compared to 2019 was higher for fentanyl (1410 × 920 mcg/patient), parenteral methadone (42 × 37 mg/patient), and remifentanil (25 × 22).
The study found that the in-hospital consumption of some potent intravenous opioids, especially fentanyl and methadone, increased during the COVID-19 pandemic at participating hospitals. In parallel, there was also a significant rise in the consumption of enteral methadone, a drug generally used to discontinue the prolonged use of parenteral opioids. These findings coincided with the increase in hospitalizations due to COVID-19 in Brazil in two waves, at the beginning and end of 2020.
I remember looking for the British protocols of palliative care and how they got tweaked and applied to covid patients, I was trying to understand if it was actually all intentional to get a spike in deaths for the optics, rather than some misconceived breakdown in everything we knew about care, love and morality, is that what we're talking about here?
Hiya, I get the argument. I just still have nuanced thinking on how something like that [ protocol changes ] could have come about, for example, the services, the not giving a shit anyway for our elderly ( not everyone ! ) , and the jaded nature of our societies, and our particular place in history......might just have led to an emergent property, rather than Blofeld & cat, I don't pretend to know much about what I'm talking about.
What are the chances of a smoking gun in our lifetime, I suppose is what I think, so the goal must be to remove the chances of those horrible possibilities occurring as much as possible, say starting with non-profit and fully transparent care for our loved-ones, how then could they be fucked over like suggusted, and whose doing that, me not so much admittedly.
I wrote an essay ‘Contemplations in Pandemic Times’ back in 2022 mentioning your research and oddities observed in Northern Italy. I sent the essay at the time to many key people then engaged in the critical analysis of the Covid plandemic.
Maybe my essay is of use to you. I am unable to post the essay due to it's length. (I can send you the PDF with all active links if you provide me with a way to do this).
Thank you for your immense contribution uncovering details of the pseudo-medical assault perpetrated on all of us.
When I first heard of the protocols involving midazolam and morphine I flew into a rage.
My PhD was on the effects of opiates on respiratory reflexes and rhythm.
By sheer coincidence I studied the fentanyl series of synthetic opiates (alfentanil, sufentanil, fentanyl, carfentanil and one other)
They varied in potency and most remarkably their duration of action.
I recall they were invented by Janssen Pharmaceuticals in the 1970s.
I called a professor of pharmacology I know in London and we got onto a mutual acquaintance, an Italian professor of respiratory medicine. The latter was distressed because he could see inappropriate treatment all around him.
Eventually he proposed an informal comparison of outcomes between one hospital and his piece of the action.
A couple of weeks later, the score card was starkly different for the group using sedation, intubation and ventilation compared with conservative treatments.
I've read many testimonials to medical staff that dissented administration.
Yet it looks like these protocols got done by and large, across countries.
Is it that not many humans are actually needed to administer drugs to large numbers of people, or that doctors ( or nurses ) generally don't differ when it comes down to it ?
It amazes me that they were facing a respiratory virus "pandemic" and the first thing they reach for is a sedation for end of life care. Does it not make more sense to look to the arsenal you have and use in every previous respiratory infection outbreak and make sure that you have all the treatments for this in abundance, the last thing should be a respiratory depressant.
I know. Extraordinary.
When people were physically fighting over toilet paper I bought oranges because I was preparing for a cold...not sure what they were worried about?
What was really going on with that toilet paper bizzo?
And other scarcity in the bigger supermarkets owned by corporations.
Any evidence found yet that this was a set up to cause panic and distress?
Because it certainly looks suspicious to me.
There was very little use of antibiotics to treat the pneumonia.
Three years later the indispensable truth of the Italian story is once you scratch beneath the surface of the official narrative of the Covid Pandemic it turns out to be a bottomless snake pit of distortions, manipulations and outright lies.
Any excess deaths in Spring 2020 in Northern Italy were an artifact of already existing health conditions in an aging population, the obliteration of the existing health care infrastructure, massive industrial pollution creating chronic conditions, media generated hysteria, savage government lockdowns and administrative murder of the already fragile.
These iatrogenic deaths of fragile people were the result of the social order and public health despotism and then used to give the impression that there was “a deadly virus” circulating.
The only pandemic was one of violent government and biomedical assault against people.
The evidence from Italy in 2020 exposes the official “Covid” narrative for what it is- a cold-blooded organized deception.
There was no pandemic.
https://21stcenturywire.com/2023/03/07/italy-2020-inside-covids-ground-zero-in-europe/
In France, a GP in the country published a letter she received with instructions what to do in case she suspected an elderly person presents with "Covid symptoms". = give them Hypnovel = Midazolam. This letter was a cilculaire sent to all GPs,
She was so socked that she published the letter and I believe retired from her post after.
I so wish I saved the article with the letter :(
When I mentioned these facts to family and friends, just as something to consider, I got 'what are you talking about !'
That's my most heartbreaking, and incitefull, takeaway from all this, which I guess I have been lucky to only learn relatively painlessly.
There is a human tendency to act like this, this GP is an image of some of the best of us
"Suddenly needed" 🚩
Adding on:
1) There are similar reports from other countries, e.g., high use in critical care units reported in France, March 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972643/
2) A Midazolam injection shortage in the U.S. reported was by the FDA on Apr 2, 2020. (Midazolam = Versed, made by Pfizer) When I asked someone I know who works in the medical supply industry about the shortage, she said by the time such shortages are reported by the FDA, it's "old news" to those who are doing the purchasing (for hospitals, etc.). She was quite surprised when I showed her the timing (April 2, 2020), because the implication is that there was very high use in the preceding weeks, if not months. A group of "experts" even wrote a letter to states that use the drug in capital punishment, requesting them to release it from their stockpiles to help treat COVID patients. https://www.theguardian.com/us-news/2020/apr/13/death-penalty-states-coronavirus-stockpiled-drugs I have mixed views on what was behind this letter, but at the time, it helped push the Deadly Spreading Virus narrative...and the idea that such drugs were "needed" for placing/sustaining patients on ventilators.
3) High doses of midazolam were reported for use during with ICU patients in this study of medications used in 47 NY hospitals. https://pubmed.ncbi.nlm.nih.gov/32712675/ I continue to be disturbed by the rhythmic nature of the census (blue) line.
4) Typical doses of midazolam are "associated with respiratory depression and cardiac arrest when used in combination with an opioid, particularly in the elderly, although all ages are at risk for respiratory depression," per this 1997 review https://pubmed.ncbi.nlm.nih.gov/9258787/
5) In 2014, Emergency Medical Services in Chicago implemented a new protocol for management of patients with behavioral emergencies using midazolam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234702/ I would love to know how many & which big-city EMS systems in the U.S. and elsewhere had also normalized using the drug in this manner prior to 2020. Noteable finding: Six adverse events in which midazolam was the suspected culprit: hypotension, hypoxia, unresponsiveness, traumatic cardiac arrest (n =1), and worsening agitation (n = 2). For the nine cases, all happened after a single 5 mg dose administered via IM (n = 6) or IN (n = 3) routes. Two of those involved giving midazolam after naloxone was administered (opioid OD drug). Such effects remind me of the hypoxia reports out of NYC and unusual number of younger-adult COVID deaths in hospitals...
Add this to the mix-
DISCUSSION
Study findings and putative explanations
Our study found that COVID+ve decedents received significantly higher opioid doses than matched prepandemic or intrapandemic control patients. This finding was moderately robust: it was consistent in each 24-hour time period within the last 72 hours of life, and further
bolstered by finding that dying of COVID-19 was independently associated (aOR=2.6) with a parenteral MEDD≥30 mg in the last 24 hours of life. COVID+ve decedents had significantly higher maximum 24-hour propofol use in ICU compared with control group decedents. Also, higher lorazepam and midazolam doses were used in the COVID+ve group than either of the other groups; the difference was only statistically significant in relation to lorazepam. Collectively, these findings regarding opioid and sedative use support our study hypothesis that the requirement for these medications is higher in hospitalised patients dying of COVID-19 infection.
In subgroup analyses, COVID+ve ICU decedents had significantly higher opioid use than ICU decedents in either of the control groups, which was evident in the last 24 hours (T1) and over the last 72 hours of life, suggesting that dying in ICU with COVID-19 infection is particularly associated with increased opioid and propofol requirements. These findings warrant a symptom profile evaluation of those dying of COVID-19.
https://bmjopen.bmj.com/content/bmjopen/13/9/e075518.full.pdf
A spokesperson from Accord Healthcare, one of five manufacturers of the drug, told The Pharmaceutical Journal that it had to gain regulatory approval to sell French-labelled supplies of midazolam injection to the NHS, after having already sold two years’ worth of stock to UK wholesalers “at the request of the NHS” in March 2020.
The DHSC said the request for extra stock was part of “national efforts to respond to the coronavirus outbreak”, which included precautions “to reduce the likelihood of future shortages”.
Midazolam is listed by the Royal College of Anaesthetists as a “first-line” sedative in the management of COVID-19 patients, and warns in guidance published on 2 April 2020 that it “may be subject to demand pressure”.
Matt Hancock, the UK health secretary, told the House of Commons Health and Social Care Select Committee on 17 April 2020 that intensive therapy unit medicines — including midazolam — are part of “a delicate supply chain” as they “are made in a relatively small number of factories around the world”.
While the DHSC confirmed that midazolam is still available to both primary and secondary care, it added that some suppliers of the sedative had limited or no stock availability.
A spokesperson from Accord Healthcare told The Pharmaceutical Journal on 11 May 2020 that it was out of stock of midazolam injection after the NHS requested it “place all of its stock of midazolam — equivalent to around two year’s forecasted supply — into its wholesale partners”, even though the manufacturer “does not currently have any NHS contracts in England” to supply the drug.
“As a result of the NHS request [in March 2020], we are subsequently out of stock,” said Peter Kelly, managing director of Accord Healthcare.
However, he added that the Medicines and Healthcare products Regulatory Agency (MHRA) had given the manufacturer approval “for some French label stock — another 22,000 packs — to be sold into the NHS and [we] are currently waiting for the MHRA’s direction on where to place the stock”.
The manufacturer said the French stock only includes midazolam at the strength of 1mg/mL in 5mL, while the initial supply in March 2020 contained a variety of four different strengths.
https://pharmaceutical-journal.com/article/news/supplies-of-sedative-used-for-covid-19-patients-diverted-from-france-to-avoid-potential-shortages
That's a great find, thanks.
How about this one from 2018?
Seizure Drug Approval Expands Countermeasures for Chemical Weapons Attack
"The U.S. Food and Drug Administration approval in Sep 2018 of the drug Seizalam® (midazolam injection) as an anti-seizure medication, provided the nation with a medical countermeasure (MCM) for people exposed to chemicals that cause prolonged seizures, whether those situations are in combat, domestic accidents or an intentional attack.
Developed by Meridian Medical Technologies, Midazolam originally was approved by FDA for use as a sedative. This recent FDA approval of intramuscular midazolam (tradename Seizalam) for status epilepticus expands the possible uses of the drug."
https://globalbiodefense.com/2018/10/31/seizure-drug-approval-expands-countermeasures-for-chemical-weapons-attack/
France:
Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units
Tension in the supply of highly consumed drugs for patients with COVID-19 (propofol, midazolam, curares) led the French government to set up a centralized supply of hospitals with distribution based on the number of resuscitation beds in March 2020.
...
Results
For the 358 establishments (47% public, 53% private), dispensations in CCU in March 2020 compared to March 2019 increased, respectively: propofol (+81%), midazolam (+125%), cisatracurium (+311%), atracurium (+138%), rocuronium (+119%); and decreased for anaesthesia: propofol (−27%), midazolam (-10%), cisatracurium (−19%), atracurium (−27%), rocuronium (+16%).
...
Conclusions
Variation of dispensations between CCU and others was directly related to the increase of COVID patients in CCU and the decrease in surgical activity.
...
During the first wave of the COVID-19 pandemic, the maximal alert in French hospitals was announced on March 13th 2020. Consequently, non-urgent surgical activity was postponed or cancelled. Priority was given to Intensive Care Units (ICU) for fear of running out of essential drugs for critical care patients.
...
The status of stocks of targeted drugs (propofol, midazolam, atracurium, cisatracurium, rocuronium) was already registered in the "MaPUI" software (MaPUI Labs, Cesson Sévigné, France), created for this purpose by a French start-up.
...
The variation of dispensations April 2019 / April 2020 for critical care units further evolved and resulted in an increase, respectively: propofol (+165%), midazolam (+204%), cisatracurium (+302%), atracurium (+350%), rocuronium (+43%). For anesthesia, it resulted in a decrease: propofol (−70%), midazolam (−67%), cisatracurium (−55%), atracurium (−65%), rocuronium (0%).
A shortage of at least one of the five drugs concerned by the survey was reported by 28% of establishments.
https://joppp.biomedcentral.com/articles/10.1186/s40545-022-00425-z
Seems like there may have been a perceived need to try out/simulate a chemical attack response plan, no?
https://chemm.hhs.gov/countermeasure_midazolam.htm
That is the same study I cited in my original reply :)
It's a good one.
Brazil
The use of parenteral fentanyl showed an increase in the total consumption in 2020 compared to 2019 (216,817,273 × 171,240,825 mcg). In 2019, consumption was stationary, with the highest mean weekly consumption being 588 mcg in EW 10. On the other hand, in 2020, there were two significant upward trends in total consumption, coinciding with the two waves of Covid-19 (gamma and delta variants of SARS-CoV-2).
The absolute number of patients included in 2020 was lower than in 2019 (310,281 × 401,602) (Table 2 and Fig. 5). Despite this reduction, mean opioid consumption per patient compared to 2019 was higher for fentanyl (1410 × 920 mcg/patient), parenteral methadone (42 × 37 mg/patient), and remifentanil (25 × 22).
The study found that the in-hospital consumption of some potent intravenous opioids, especially fentanyl and methadone, increased during the COVID-19 pandemic at participating hospitals. In parallel, there was also a significant rise in the consumption of enteral methadone, a drug generally used to discontinue the prolonged use of parenteral opioids. These findings coincided with the increase in hospitalizations due to COVID-19 in Brazil in two waves, at the beginning and end of 2020.
https://www.nature.com/articles/s41598-023-44533-5
https://www.nature.com/articles/s41598-023-44533-5
Imagine how easy it would be to make deaths resulting from those measures look like COVID shot deaths.
Or "opioid overdose" deaths.
Or...pretty much any kind of deaths.
This is one of many reasons why analyses of mortality data MUST include setting/place of death.
I shall continue to assert that all-cause death curves around the world cannot necessarily be trusted.
I remember looking for the British protocols of palliative care and how they got tweaked and applied to covid patients, I was trying to understand if it was actually all intentional to get a spike in deaths for the optics, rather than some misconceived breakdown in everything we knew about care, love and morality, is that what we're talking about here?
https://open.substack.com/pub/aislingoloughlin/p/irelands-death-row-midazolam-doses?utm_source=direct&r=21qype&utm_campaign=comment-list-share-cta&utm_medium=web&comments=true&commentId=41934149
Yes. That was the plan. The deaths were necessary to create panic. You need panic to ensure compliance
Hiya, I get the argument. I just still have nuanced thinking on how something like that [ protocol changes ] could have come about, for example, the services, the not giving a shit anyway for our elderly ( not everyone ! ) , and the jaded nature of our societies, and our particular place in history......might just have led to an emergent property, rather than Blofeld & cat, I don't pretend to know much about what I'm talking about.
What are the chances of a smoking gun in our lifetime, I suppose is what I think, so the goal must be to remove the chances of those horrible possibilities occurring as much as possible, say starting with non-profit and fully transparent care for our loved-ones, how then could they be fucked over like suggusted, and whose doing that, me not so much admittedly.
Good work
Wow, the killing apparatus was humongous, we continuely find out more detail.
Hello Mr. Engler:
I wrote an essay ‘Contemplations in Pandemic Times’ back in 2022 mentioning your research and oddities observed in Northern Italy. I sent the essay at the time to many key people then engaged in the critical analysis of the Covid plandemic.
Maybe my essay is of use to you. I am unable to post the essay due to it's length. (I can send you the PDF with all active links if you provide me with a way to do this).
Thank you for your immense contribution uncovering details of the pseudo-medical assault perpetrated on all of us.
All The Best!
Albrecht
Hi - sent to you a direct message on this platform. Would love to see it. Thanks
When I first heard of the protocols involving midazolam and morphine I flew into a rage.
My PhD was on the effects of opiates on respiratory reflexes and rhythm.
By sheer coincidence I studied the fentanyl series of synthetic opiates (alfentanil, sufentanil, fentanyl, carfentanil and one other)
They varied in potency and most remarkably their duration of action.
I recall they were invented by Janssen Pharmaceuticals in the 1970s.
I called a professor of pharmacology I know in London and we got onto a mutual acquaintance, an Italian professor of respiratory medicine. The latter was distressed because he could see inappropriate treatment all around him.
Eventually he proposed an informal comparison of outcomes between one hospital and his piece of the action.
A couple of weeks later, the score card was starkly different for the group using sedation, intubation and ventilation compared with conservative treatments.
The other was lofentanil.
Can you provide the name of the Italian professor? Thanks
I don’t recall it & unfortunately I’m now persona non grata with the U.K. person, despite knowing them since the late 1980s at university. Sorry.
Jonathan, i always found the body language and word use of this lady very disturbing.
https://biologyphenom.substack.com/p/scottish-covid-19-inquiry-impact-7fc
I've read many testimonials to medical staff that dissented administration.
Yet it looks like these protocols got done by and large, across countries.
Is it that not many humans are actually needed to administer drugs to large numbers of people, or that doctors ( or nurses ) generally don't differ when it comes down to it ?
And same in Sweden
Harold Shipman Versus Obama